


# MEMBER IMPACT

SUMMARY 2024-5



# OUR IMPACT

**This Member Impact Summary 2024-25 reflects a year of transformation for AusBiotech. Building on AusBiotech's nearly 40-year legacy, we continued strengthening Australia's future in life sciences. We welcomed new leadership, expanded our expert team, and sharpened our strategic focus.**

**AusBiotech has remained steadfast in advocating for Australia's life science sector, fostering connections, and enabling knowledge sharing. With a growing membership and a united sector voice, we are ensuring Australian life science companies thrive locally and globally. We remain disciplined in our priorities and committed to a member-centric culture that advances a thriving life sciences ecosystem.**

## We advocate and shape policy

AusBiotech is working to unify the sector's voice through strategic partnerships and advance a strong, advocacy agenda to support our members and champion the life sciences sector as critical to Australia's health, economic resilience, and national security.

- We have forged strong working relationships with peer national peak bodies and signed new partnership agreements of strategic significance, including with ANDHealth. We also signed memorandums of understanding with state-based organisations. These collaborations reflect our commitment to cohesive national advocacy and sector-wide alignment.

- We hosted the first ever National Biotech and Medtech Development and Commercialisation Summit in partnership with MTPConnect, bringing together more than 100 industry experts to chart a united set of priorities for our sector. Supported by the National Biotech and Medtech Development and Commercialisation Discussion Paper.
- Our 2025-26 Pre-Budget Submissions were delivered in partnership with Medicines Australia and MTPConnect. Our 2025 Election Platform received positive feedback across all levels of government.



- We held member roundtables on domestic and international policy matters, including the Australian Government's National Health and Medical Research Strategy. We also made submissions to state and federal consultations, including the Strategic Examination of R&D, Treasury's Future Made in Australia 'Front Door' for major investment proposals, and Therapeutic Goods Administration reviews.
- Our policy team actively engages with policymakers, including through roundtables such as our early 2025 session with Rosemary Huxtable AO PSM on the National Health and Medical Research Strategy, and other critical stakeholder meetings.
- In March 2025, to empower our members, we launched Engage for Impact — an exclusive event series designed to demystify political processes and increase industry influence, hosted by the Hon Milton Dick MP, Speaker of the House of Representatives.

Our advocacy priorities have remained clear.

Our key advocacy asks include:

- Developing Australia's first whole-of-government National Life Sciences Strategy to set clear policy priorities and eliminate gaps and overlaps.
- Establishing an Australian Life Sciences Council – a partnership between industry and government – to drive this strategy, address sector challenges and ensure value for investment.
- Investing in data collection to drive innovation and improve policy and decision-making.
- Recognising life sciences as a priority under the government's industry policy frameworks.

In response to changing geopolitical and trade environments, our policy team has focused on international relations supporting members, working closely with the Australian Government, the Department of Foreign Affairs and Trade, Austrade, and other key departments.

Through disciplined advocacy and collaborative leadership, AusBiotech continues to deliver clear and consistent asks to government that reflect members' needs at a pivotal time for our sector.

## We created national and global connections

Our unmatched national and global convening power continues to unite Australia's life sciences ecosystem, advancing innovation through connection and collaboration. We are proud to have delivered an industry-leading portfolio of conferences and events that attracted local and global life sciences leaders, investors, service providers and government supporters.

- **BIO 2024 delegation and preparation for 2025: (San Diego, 3-6 June):** AusBiotech collaborated with BIO to co-host the 'Investing in Australia' roundtable, uniting government, industry leaders, and investors — including the Hon Ed Husic MP, Minister for Industry and Science — to explore opportunities to grow Australia's life sciences sector through collaboration and investment. We also promoted Australia's biotech capabilities via the International Council of Biotechnology Associations and the 'Access Australia' platform. Preparations are now underway for our involvement in BIO 2025.
- **AusBiotech 2024 (Melbourne, 30 October-1 November):** This record-breaking event attracted 1,600 delegates, with an industry-leading program that brought in the largest number of international delegates in our history.

- **AusBioInvest 2024 (Melbourne, 29 October):** Australia's premier life sciences investment event featured 26 company pitches that connected innovators with global investors, leading international speakers, and top biotech opportunities.
- **Women in Life Sciences 2025 (Sydney, 7 March):** Our first-ever Women in Life Sciences Leadership Summit empowered women shaping the future of health, biotech, pharma, and medtech. The summit was followed by the 9th annual WILS Luncheon, co-hosted with Medicines Australia, attended by over 600 sector leaders to mark International Women's Day.
- **AusBiotech Medtech Invest 2025 (Sydney, 6-8 May):** Nearly 500 delegates engaged with more than 100 expert speakers to explore Australia's 900-strong medical technology sector. Our program expertly delivered critical conversations addressing topics ranging from manufacturing and procurement to regulatory and reimbursement.
- **AusMedtech Invest 2025 (Sydney, 7 May):** Australia's premier medtech investment event featured cutting-edge company pitches, global investors, and expert insights — connecting innovators with capital across diagnostics, devices, and digital health.
- **BioCheers and BioBriefings:** Our state-based education and networking events continue to unite our members and the wider life sciences community, bringing our sector's heartbeat together to connect.

## We enabled learning and knowledge-sharing

As a trusted conduit for sector-wide learning across Australia's life sciences ecosystem, AusBiotech continues to connect members with expert insights, emerging trends, and best practices through our Committees and Advisory Groups.

In 2025, we are continuing to enhance knowledge-sharing with the launch of our member-only newsletter **THRIVE** and our new **Spotlight** series, a video campaign celebrating member stories of innovation, collaboration and impact. Launching in May 2025, each **Spotlight** episode will highlight the breakthroughs and partnerships shaping Australia's thriving life sciences ecosystem.

## STRATEGIC PARTNERSHIPS.

### Cell and Gene Catalyst

Australia's Cell and Gene Catalyst (the Catalyst) is a joint venture between AusBiotech and Medicines Australia. It aims to position Australia as a global leader by creating an end-to-end world-class value chain to discover, develop, manufacture, and distribute cell and gene therapies to Australian patients, all while creating jobs, commercialising research, and exporting Australian therapies to the world.

The Catalyst is supported by a strategic Steering Group and expert working groups focused on priority areas: policy and advocacy, collaboration, manufacturing and knowledge-sharing, and workforce development.

### Industry Growth Program

As an Industry Partner Organisation (IPO) under the Australian Government's Industry Growth Program (IGP), AusBiotech officially launched its IGP Program in March at the Translational Research Institute. This initiative aims to support Australian startups and small to medium-sized enterprises (SMEs) in commercialising their innovations. As an IPO, AusBiotech delivers commercialisation advisory services for 26 participants, leveraging our extensive industry expertise and networks.

To support IGP participants, AusBiotech has a network of expert mentors providing tailored commercialisation guidance through a structured mentoring program. With nearly 80 per cent of Australia's life sciences companies classified as SMEs, programs like the IGP are crucial in fostering research translation, investment readiness and global connections.